# Converge Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/converge-bio

- Industry: Biotechnology
- Headquarters: Wilmington, US
- Website: www.converge-bio.com/
- Total disclosed funding: $31M
- Latest round: Series A (Jan 13, 2026)
- Investors on record: 4

## About

Based in Delaware, US, and founded in 2024 by co-founders Doz Gertz and Oded Kalev, Converge Bio specialises in integrating generative artificial intelligence with biological data within the biotechnology and pharmaceutical sectors. In January 2026, Converge Bio, Inc. raised USD 25 million in series A funding led by Bessemer Venture Partners, with participation from Saras Capital, Vintage Investment Partners, and TLV Partners.

Converge offers a comprehensive suite of products and services that leverage generative AI to enhance drug discovery and development processes in the biotech and pharmaceutical sectors. The platform integrates large language models (LLMs) specifically trained on biological data to address critical challenges such as small molecule optimisation, antibody enhancement, target discovery, vaccine design, biomarker identification, and protein engineering. By utilising advanced algorithms and a bio-LLM library, the platform improves the efficacy and safety of therapeutics. The company's client base includes biotech and pharmaceutical companies. The company plans to utilize the January 2026 funding to further develop its artificial intelligence drug discovery platform.

## Funding rounds

- Series A, Jan 13, 2026, $25M — Vintage Investment Partners, Bessemer Venture Partners, TLV Partners, Saras Capital
- Seed, Nov 20, 2024, $5.5M — TLV Partners

## Investors

- TLV Partners (https://capitalatlas.ai/funds/tlv-partners) — Seed, Series A
- Vintage Investment Partners (https://capitalatlas.ai/funds/vintage-investment-partners) — Series A
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series A
- Saras Capital (https://capitalatlas.ai/funds/saras-capital) — Series A